3082-LB: The Selective Amylin Analog Eloralintide Enhanced Weight-Loss Efficacy when Combined with Tirzepatide in DIO Rats
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-3082-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von DANIEL A. BRIERE und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Eloralintide (LY3841136) is a long-acting and selective amylin analog in clinical development for the treatment of obesity. Given the complementary mechanisms of action exhibited by amylin and incretins, this study sought to evaluate the effects of combined therapy—both co-administration and adjunctive use—of eloralintide with tirzepatide, a GIP and GLP-1 receptor agonist, on food intake, body weight, and body composition in diet-induced obese (DIO) rats.
Methods
For co-administration studies, male Long Evans DIO rats were subcutaneously dosed every 3 days with either vehicle, tirzepatide, eloralintide, or a combination of tirzepatide and eloralintide for 2 weeks. For adjunctive studies, DIO rats were dosed for 2 weeks with tirzepatide, followed by the addition of eloralintide to ongoing tirzepatide for an additional 2 weeks. Body weights and food intake were measured daily, and body composition was measured at baseline and the end of the study using QNMR.
Results
In DIO rats, treatment with either eloralintide or tirzepatide significantly reduced food intake and lowered body weights. The combination of eloralintide and tirzepatide, as a co-administration and as adjunctive treatment, further enhanced food intake reductions, body weight lowering, and fat mass loss greater than treatment with either agent alone.
Conclusion
The combination of eloralintide plus tirzepatide in DIO rats produced augmented weight loss greater than the effects of individual therapies. These observations support clinical investigation of eloralintide as an obesity therapeutic in combination with tirzepatide. Disclosure D.A. Briere: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. L. O'Farrell: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. C. Howard: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. D.M. Allen: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. C. Clutinger: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. T. Coskun: Employee; Current; Eli Lilly and Company. J.S. Moyers: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company. A.L. Cox: Employee; Current; Eli Lilly and Company. Stock/Shareholder; Current; Eli Lilly and Company.
Zitieren
APA
BRIERE, D. A., O'FARRELL, L. S., HOWARD, C., ALLEN, D. M., CLUTINGER, C., COSKUN, T., MOYERS, J. S., & COX, A. L. (2026). 3082-LB: The Selective Amylin Analog Eloralintide Enhanced Weight-Loss Efficacy when Combined with Tirzepatide in DIO Rats. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-3082-lb
Vancouver
BRIERE DA, O'FARRELL LS, HOWARD C, ALLEN DM, CLUTINGER C, COSKUN T, et al. 3082-LB: The Selective Amylin Analog Eloralintide Enhanced Weight-Loss Efficacy when Combined with Tirzepatide in DIO Rats. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-3082-lb
BibTeX
@article{BRIERE2026,
author = {BRIERE, DANIEL A. and O'FARRELL, LIBBEY S and HOWARD, CASSIDY and ALLEN, DAWN M. and CLUTINGER, CATHLEEN and COSKUN, TAMER and MOYERS, JULIE S. and COX, AMY L.},
title = {3082-LB: The Selective Amylin Analog Eloralintide Enhanced Weight-Loss Efficacy when Combined with Tirzepatide in DIO Rats},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-3082-lb}
}
EUVIMED